MMNFF · Medmen Enterprises, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.07M | $31.83M | $33.67M | $39.12M | $39.42M | $35.11M | $44.07M | $32.03M | $39.67M | - |
| Cost of Revenue | $18.04M | $14.50M | $15.19M | $19.88M | $18.04M | $18.65M | $31.24M | $18.71M | $20.28M | - |
| Gross Profit | $17.21M | $15.05M | $14.86M | $19.24M | $12.30M | $16.46M | $12.83M | $13.32M | $19.39M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $25.70M | $18.34M | $17.85M | $35.30M | $25.52M | $30.24M | $60.32M | $28.94M | $54.09M | - |
| Total Operating Expenses | $37.08M | $21.79M | $20.48M | $44.40M | $37.30M | $10.48M | $81.49M | $40.15M | $70.95M | - |
| D&A | $2.77M | $1.41M | $3.97M | $3.85M | $2.77M | $8.07M | $3.71M | $4.45M | $3.36M | - |
| Operating Income | ($20.09M) | ($6.74M) | ($5.62M) | ($25.15M) | ($20.09M) | $5.98M | ($68.67M) | ($26.83M) | ($51.56M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($5.37M) | $1.06M | $2.19M | ($8.14M) | ($32.73M) | $12.28M | ($14.65M) | ($32.21M) | $6.02M | - |
| Net Income | ($29.75M) | ($19.03M) | $4.16M | $20.36M | $30.04M | $32.85M | ($93.25M) | ($9.73M) | ($87.25M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.63M | $15.61M | $21.10M | $10.80M | $14.41M | $78.22M | $11.87M | $31.75M | $10.31M | $9.31M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $14.67M | $13.68M | $9.12M | $10.01M | $11.93M | $19.40M | $20.09M | $17.05M | $22.64M | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $91.08M | $100.21M | $98.68M | $161.50M | $170.96M | $165.51M | $96.68M | $117.41M | $84.04M | - |
| Total Assets | $215.59M | $238.48M | $251.13M | $323.22M | $431.98M | $531.89M | $472.46M | $487.33M | $574.26M | - |
| Current Liabilities | $474.28M | $237.64M | $233.58M | $326.42M | $375.11M | $345.24M | $288.61M | $282.68M | $198.09M | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $572.98M | $567.27M | $564.70M | $641.74M | $679.12M | $732.93M | $726.10M | $709.71M | $751.15M | - |
| Stockholders' Equity | $122.36M | $146.44M | $160.53M | $151.81M | $205.57M | $251.13M | $191.76M | $213.12M | $181.53M | - |
| Retained Earnings | ($941.14M) | ($913.80M) | ($897.61M) | ($905.42M) | ($820.97M) | ($772.19M) | ($717.23M) | ($679.60M) | ($631.37M) | - |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($9.61M) | - | - | ($18.16M) | - | - | ($42.07M) | - |
| Investing Cash Flow | - | - | $51.48M | - | - | $9.66M | - | - | ($13.15M) | - |
| Financing Cash Flow | - | - | ($31.56M) | - | - | $8.63M | - | - | $63.70M | - |
| CapEx | - | - | - | - | - | $280.6K | - | - | $17.98M | - |
| Free Cash Flow | - | - | - | - | - | ($18.44M) | - | - | ($60.04M) | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q2 '22 | Q3 '22 | Q1 '22 | Q2 '21 | Q3 '21 | Q1 '21 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 59.2% | 47.3% | 44.1% | 49.2% | 31.2% | 46.9% | 29.1% | 41.6% | 48.9% | - |
| Operating margin | -69.1% | -21.2% | -16.7% | -64.3% | -51.0% | 17.0% | -155.8% | -83.8% | -130.0% | - |
| EBITDA margin | -59.6% | -16.7% | -4.9% | -54.4% | -43.9% | 40.0% | -147.4% | -69.9% | -121.5% | - |
| Net margin | -102.3% | -59.8% | 12.4% | 52.0% | 76.2% | 93.6% | -211.6% | -30.4% | -220.0% | - |
| Free cash flow margin | - | - | - | - | - | -52.5% | - | - | -151.4% | - |
| FCF / Net income | - | - | - | - | - | -0.56 | - | - | 0.69 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 88.4% | 57.6% | 53.0% | 90.2% | 64.8% | 86.1% | 136.9% | 90.4% | 136.4% | - |
| Effective tax rate | - | - | 34.5% | -66.6% | - | 27.2% | - | - | - | - |
| Return on assets | -13.8% | -8.0% | 1.7% | 6.3% | 7.0% | 6.2% | -19.7% | -2.0% | -15.2% | - |
| Return on equity | -24.3% | -13.0% | 2.6% | 13.4% | 14.6% | 13.1% | -48.6% | -4.6% | -48.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.19 | 0.42 | 0.42 | 0.49 | 0.46 | 0.48 | 0.33 | 0.42 | 0.42 | - |
| Quick ratio | 0.16 | 0.36 | 0.38 | 0.46 | 0.42 | 0.42 | 0.27 | 0.36 | 0.31 | - |
| Cash ratio | 0.02 | 0.07 | 0.09 | 0.03 | 0.04 | 0.23 | 0.04 | 0.11 | 0.05 | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.76 | 1.63 | 1.56 | 2.13 | 2.10 | 2.12 | 2.46 | 2.29 | 3.16 | - |
| Liabilities / Assets | 2.66 | 2.38 | 2.25 | 1.99 | 1.57 | 1.38 | 1.54 | 1.46 | 1.31 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | 0.13 | 0.13 | 0.12 | 0.09 | 0.07 | 0.09 | 0.07 | 0.07 | - |
| Inventory turnover | 1.23 | 1.06 | 1.67 | 1.99 | 1.51 | 0.96 | 1.55 | 1.10 | 0.90 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 297d | 344d | 219d | 184d | 241d | 380d | 235d | 333d | 407d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -26.2% | -18.6% | -4.1% | -11.2% | 23.1% | -11.5% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 39.8% | -21.8% | -9.7% | 50.0% | -7.6% | -15.1% | - | - | - | - |
| Operating income growth (YoY) | 0.0% | 73.2% | - | 63.4% | 25.1% | - | - | - | - | - |
| Net income growth (YoY) | - | - | -87.3% | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | 69.3% | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -40.5% | -3.5% | -36.1% | -20.8% | -3.5% | 38.3% | - | - | - | - |
Peer comparison
Same SIC group: Retail-Retail Stores, NEC
Comparing MedMen Enterprises against the 5 most active filers in the same SIC group.